OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Cancer is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)

Article	Citations
Starting a new job	1212
New pathogen on the block	1047
Feeding latent brain metastasis	963
An inhospitable site	871
MYC inhibition, courtesy of E. coli	837
MDMX drives pre-leukaemia progression	835
Epigenetic remodelling drives fibroid development	780
Glycogen condensates drive tumorigenesis by trapping Hippo kinases	472
Computing brain metastasis impact	450
Breast milk for breast cancer detection	431
Fructose takes a detour to feed cancer	410
Characterization of the B cell receptor repertoire in melanoma	371
Hubs of transcriptional activity	357
To sleep, perchance to spread	343
Linking pancreatic renewal and cancer initiation	328
Proximity labelling to study chromatin interactomes	284
Obesity-induced neutrophil reprogramming	262
The road less travelled	262
Peto’s paradox put to the test	259
Quantum probes in cancer research	256
Programming immune escape	256
Functional lineage tracing to study the clonal evolution of therapy resistance	240
Digging for treasures in the tumour interactome	235
Oncofetal reprogramming in tumour development and progression	225
In vivo labelling system to study cell neighbourhoods	223

Emerging strategies to investigate the biology of early cancer	221
The language of chromatin modification in human cancers	219
Conventional chemotherapy: millions of cures, unresolved therapeutic index	219
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs	211
Artificial intelligence in cancer research, diagnosis and therapy	200
Polyamines in cancer: integrating organismal metabolism and antitumour immunity	195
Shining a light on tumour behaviour	191
Publisher Correction: Programmed death ligand 1 signals in cancer cells	190
Cancer proteogenomics: current impact and future prospects	186
Neutrophils: a roadblock for immunotherapy	186
INVADEseq to study the intratumoural microbiota at host single-cell resolution	185
Tumour fatty acid metabolism in the context of therapy resistance and obesity	180
Tumour avatars to model patients’ responses to immunotherapy	174
Dissecting metastasis using preclinical models and methods	173
Defining and using immune archetypes to classify and treat cancer	171
Studying large genomic deletions with MACHETE	170
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies	168
Understanding tumour endothelial cell heterogeneity and function from single-cell omics	156
Judith Campisi (1948–2024)	153
Cancer burden in low-income and middle-income countries	149
Investigating immune cells across time in vivo	148
Combinatorial strategies to target RAS-driven cancers	147
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	140
Approaching cancer during pregnancy	136
Extrachromosomal DNA in cancer	134
Revealing genomic secrets of archival FFPE samples	126
Inferring cancer metabolism from gene-expression data	125
CAF-induced physical constraints controlling T cell state and localization in solid tumours	124
The present and future of the Cancer Dependency Map	123
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	122
Creating a dietary vulnerability	119
Intercepting gastric cancer	118
Long noncoding RNAs in cancer metastasis	118
Rational combination of cancer therapies with PD1 axis blockade	113
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	113
tRNA supply and demand	109
Cell states can give tumorigenesis a head start	108
Obesity as a promoter in BRCA mutation carriers	107
Lifestyle interventions for cancer survivors	106
Switching on cancer survival mechanisms	104
Metabolic mechanisms of medulloblastoma metastasis	102
Reflecting on 20 years of progress	90
Addressing systemic racism as the cancer of Black people: equity ethic-driven research	88
Glutamylation is good for stability	88
Gasdermin E shields PDAC	86
Epigenomic heterogeneity as a source of tumour evolution	83
AR blockers augment melanoma treatment	82
Cholesterol-fuelled glioblastoma	82
Microbiota links to immunotherapy toxicity	80
How medical anthropology can contribute to cancer research	80

Eliminating false positives